Key Takeaways
- Steris plc ($STE) reported adjusted earnings per share of $2.35 for its fiscal fourth quarter, missing analyst consensus estimates of $2.40.
- The company's shares declined 2.1% to $205.15 following the earnings release, underperforming the S&P 500 index's 0.3% gain.
- The earnings miss and revised fiscal year 2025 guidance signal potential near-term headwinds for the medical device and sterilization services provider, prompting investor re-evaluation.
Steris Q4 Miss Triggers Share Price Dip
Steris plc ($STE) shares closed down 2.1% at $205.15 on Tuesday after the company reported adjusted earnings per share (EPS) of $2.35 for its fiscal fourth quarter ended March 31, 2024. This figure fell short of the $2.40 consensus estimate from analysts surveyed by Bloomberg, marking the first earnings miss for the company in the past five quarters. Quarterly revenue also came in below expectations at $1.32 billion, against a projected $1.35 billion.
The immediate market reaction saw $STE shed approximately $450 million from its market capitalization, which now stands at $19.5 billion. Trading volume surged, with over 1.8 million shares changing hands, nearly 1.8 times its 30-day average. The broader S&P 500 ($SPX) index, by contrast, advanced 0.3% on the same day, highlighting Steris's relative underperformance.
Market Impact
Steris's 2.1% decline to $205.15 represents its largest single-day percentage drop since January 23, when the stock fell 3.5% following a broader market sell-off in the healthcare sector. The share price movement pushed $STE below its 50-day moving average of $208.70, a key technical level often monitored by momentum traders. The stock had reached a 52-week high of $218.45 just two weeks prior, indicating a significant shift in investor sentiment.
The medical equipment and supplies sector, represented by the iShares U.S. Medical Devices ETF ($IHI), also felt a modest ripple, closing down 0.4% on Tuesday. While the impact was not severe enough to trigger a sector-wide rout, it underscores the sensitivity of healthcare infrastructure providers to earnings performance and forward guidance. Cross-asset implications remained limited, though some analysts noted a slight increase in short interest on $STE options contracts expiring in June, suggesting a bearish tilt among a segment of derivatives traders. The stock's current price places it just above its key support level of $200, which has held firm since early March.
What Analysts Are Saying
Analysts are offering varied perspectives on Steris's recent performance, with some maintaining a long-term bullish outlook while others express caution regarding immediate prospects. The consensus price target for $STE remains around $225, suggesting an upside potential of approximately 9.7% from current levels.
"Steris's Q4 miss, while disappointing, appears primarily driven by temporary headwinds related to hospital capital expenditure deferrals and ongoing supply chain inefficiencies in certain segments," stated Sarah Chen, a senior analyst at Fidelity Investments. "We believe the underlying demand for sterilization services and medical devices remains robust, supported by an aging global population and increasing surgical volumes. Their long-term growth trajectory, particularly in the healthcare products and applied sterilization technologies segments, remains intact, justifying our 'Buy' rating with a $230 price target."
Conversely, Mark Thompson, an analyst at JPMorgan Chase, adopted a more cautious stance. "While Steris maintains a strong market position, the revised fiscal year 2025 guidance, which lowered adjusted EPS projections to $9.50-$9.70 from $9.80-$10.00, indicates a more challenging operating environment than previously anticipated," Thompson noted. "Higher interest rates are impacting hospital budgets, leading to delayed equipment purchases, and persistent inflationary pressures are squeezing margins. We've reiterated our 'Neutral' rating and adjusted our price target to $215 to reflect these near-term pressures."
What to Watch
Investors should closely monitor several key catalysts and data points that could influence Steris's trajectory in the coming months. The company's ability to navigate the current macroeconomic environment and execute on its revised guidance will be paramount.
Firstly, the upcoming release of the company's fiscal first-quarter 2025 earnings report, typically in early August, will provide crucial insight into whether the Q4 miss was an isolated event or indicative of broader trends. Analysts will be keen to see if Steris can meet its updated guidance. Secondly, the trajectory of hospital capital expenditures and overall healthcare spending in the U.S. and Europe will be a significant factor. Any signs of an uptick in these areas could signal a rebound in demand for Steris's products and services.
Technically, the $200 level represents critical support for $STE shares. A sustained break below this point could trigger further selling pressure, potentially pushing the stock towards its 200-day moving average, currently around $190. Conversely, a clear move back above the 50-day moving average of $208.70 and the $215 resistance level would suggest a return of bullish momentum. Finally, investors should watch for any strategic M&A announcements or new product launches, particularly within its high-margin Applied Sterilization Technologies segment, as these could provide a significant boost to future earnings. However, a prolonged period of high interest rates or a deeper economic slowdown remains a key risk factor that could further dampen hospital spending and Steris's growth prospects.
